ImmuRx, Inc. develops adjuvant platforms for the treatment of cancers and infectious diseases. The company’s product includes CD40 compound, an antibody. Its approach reduces solid tumor mass, enhances survival times in cutaneous and hematapoietic tumor models, and protects against viral and bacterial infections in various animal models. The